ACAD
ACADIA Pharmaceuticals Inc.
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The Company has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The Company also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).
Buy US stocks in Australia starting with ACAD. Open an account and start investing today!
$3.21B
-
0.00%
1.09M
$20.03
$19.73
$19.75
$28.06
$12.24
ACAD FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in ACAD
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.